Your browser doesn't support javascript.
loading
IFN-γ-mediated control of SARS-CoV-2 infection through nitric oxide.
Silva, Bruno J de Andrade; Krogstad, Paul A; Teles, Rosane M B; Andrade, Priscila R; Rajfer, Jacob; Ferrini, Monica G; Yang, Otto O; Bloom, Barry R; Modlin, Robert L.
Affiliation
  • Silva BJA; Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California (UCLA), Los Angeles, CA, United States.
  • Krogstad PA; Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.
  • Teles RMB; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA, United States.
  • Andrade PR; Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California (UCLA), Los Angeles, CA, United States.
  • Rajfer J; Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California (UCLA), Los Angeles, CA, United States.
  • Ferrini MG; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.
  • Yang OO; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.
  • Bloom BR; Department of Health and Life Sciences, Charles R. Drew University of Medicine and Science, Los Angeles, CA, United States.
  • Modlin RL; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.
Front Immunol ; 14: 1284148, 2023.
Article de En | MEDLINE | ID: mdl-38162653
ABSTRACT

Introduction:

The COVID-19 pandemic has highlighted the need to identify mechanisms of antiviral host defense against SARS-CoV-2. One such mediator is interferon-g (IFN-γ), which, when administered to infected patients, is reported to result in viral clearance and resolution of pulmonary symptoms. IFN-γ treatment of a human lung epithelial cell line triggered an antiviral activity against SARS-CoV-2, yet the mechanism for this antiviral response was not identified.

Methods:

Given that IFN-γ has been shown to trigger antiviral activity via the generation of nitric oxide (NO), we investigated whether IFN-γ induction of antiviral activity against SARS-CoV-2 infection is dependent upon the generation of NO in human pulmonary epithelial cells. We treated the simian epithelial cell line Vero E6 and human pulmonary epithelial cell lines, including A549-ACE2, and Calu-3, with IFN-γ and observed the resulting induction of NO and its effects on SARS-CoV-2 replication. Pharmacological inhibition of inducible nitric oxide synthase (iNOS) was employed to assess the dependency on NO production. Additionally, the study examined the effect of interleukin-1b (IL-1ß) on the IFN-g-induced NO production and its antiviral efficacy.

Results:

Treatment of Vero E6 cells with IFN-γ resulted in a dose-responsive induction of NO and an inhibitory effect on SARS-CoV-2 replication. This antiviral activity was blocked by pharmacologic inhibition of iNOS. IFN-γ also triggered a NO-mediated antiviral activity in SARS-CoV-2 infected human lung epithelial cell lines A549-ACE2 and Calu-3. IL-1ß enhanced IFN-γ induction of NO, but it had little effect on antiviral activity.

Discussion:

Given that IFN-g has been shown to be produced by CD8+ T cells in the early response to SARS-CoV-2, our findings in human lung epithelial cell lines, of an IFN-γ-triggered, NO-dependent, links the adaptive immune response to an innate antiviral pathway in host defense against SARS-CoV-2. These results underscore the importance of IFN-γ and NO in the antiviral response and provide insights into potential therapeutic strategies for COVID-19.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Interféron gamma / COVID-19 / Monoxyde d'azote Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Front Immunol Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Suisse

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Interféron gamma / COVID-19 / Monoxyde d'azote Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Front Immunol Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Suisse